Cell Reports, Volume 26

Supplemental Information

PPAR_γ Interaction with UBR5/ATMIN

Promotes DNA Repair

to Maintain Endothelial Homeostasis

Caiyun G. Li, Cathal Mahon, Nathaly M. Sweeney, Erik Verschueren, Vivek Kantamani, Dan Li, Jan K. Hennigs, David P. Marciano, Isabel Diebold, Ossama Abu-Halawa, Matthew Elliott, Silin Sa, Feng Guo, Lingli Wang, Aiqin Cao, Christophe Guignabert, Julie Sollier, Nils P. Nickel, Mark Kaschwich, Karlene A. Cimprich, and Marlene Rabinovitch **1** Supplementary Information





Figure S1 PPARy interacts with the MRE11-RAD50-NBS1 (MRN) complex via NBS1 in 293T cells. – Related to Figure 1, Table S1-2.

- (A) AP-MS experiments yielded a volcano plot revealing 87 PPARγ high confidence interactors (R2) out of the 352
- 7 interactors (R1+R2). Four (in red) were validated in (C) Dotted lines represent cut-off at Log₂(Fold-Change > 1.5)
- 8 and $Log_{10}(adj. P value \le 0.05 and 1.0x10^{-9})$. R1, region 1; R2, region 2, described in Results.

- 9 (B) Representative immunoblots of PPARγ interactions in 293T nuclear extracts.
- 10 (C) Experimental set up of the BS3 crosslinking mass spectrometry (XL-MS) using tandem immunoprecipitation of 11 Eleg NIPS1 and PDA By Stron to determine NIPS1 and PDA By binding interface
- **11** Flag-NBS1 and PPAR γ -Strep to determine NBS1 and PPAR γ binding interface.
- 12 (D) Raw MS/MS data of the identified crosslinked peptides from BS3 treated beads and trypsin-digested NBS1 and
- PPARγ. Amino acid positions of the peptides are as indicated. Analyses and methods are described in experimental
 procedures.
- 15 (E) Structural mapping of the three PPARγ peptides (red) identified in (D) to PPARγ crystal structure (light green)
- 16 obtained from PDB:3DZU. This structure depicts PPARγ and RXRα (blue) complex on DNA (yellow).
- 17 (F) Putative NBS1-PPARγ binding interface as indicated by the locations of the three Xlink peptides (red). The
- Xlink lysines (K) are labeled as green in inset. PPARγ N-terminus is in light green, and its ligand-binding domain
 (LBD) is in pink.
- 20
- 21
- 22
- 23
- 24 25



27 28 29

Figure S2 Nuclear PPARy and NBS1 are in an independent cellular pool from PPARy and RXRa. – Related to Figure 1.

Fraction # 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

📥 RXRα

- 30 (A) 293T nuclear extracts expressing PPAR_γ-2xStrep and Flag-NBS1 with and without HU treatment were analyzed
- 31 by size-exclusion chromatography on a Superose 6 gel filtration column. Proteins eluted from fractions #3-25 were
- further analyzed by immunoblots to detect PPAR γ (anti-Strep), NBS1 (ant-Flag) and RXR α (anti-RXR α). Graphs
- indicate densitometry results of each protein. Region 1 and 2 (R1, R2) are highlighted in red (in immunoblots) and
- 34 yellow (in graphs) to indicate PPARγ eluted fractions. Since PPARγ-2xStrep is approximately (approx.) a 60 kDa
- protein (analyzed by silver staining in Fig. 1e), PPARγ eluted from fraction #21 (approx. 67 kDa) might be the
- 36 excess monomeric form (due to overexpression). * indicates non-specific band.
- 37 (B) mRNA expression of PPAR γ target genes with NBS1 or PPAR γ depletion. mRNA expression was normalized to 38 β -actin mRNA.
- 39 (C) Representative immunoblots of interactions between Flag-PPARγ (F-PPARγ) without the ligand binding domain
 40 (ΔLBD) and MRN.
- (E) Representative immunoblots of endogenous co-immunoprecipitation (co-IP) between nuclear UBR5, NBS1 and
 PPARγ using anti-UBR5 or anti-NBS1.
- 43 (F) Representative immunoblots of endogenous IP of PPARy with UBR5 with NBS1 depletion (siNBS1).
- 44 Error bars, mean \pm s.e.m. (B). siC, siControl. Two-way ANOVA test with Fisher's LSD test (B). *, P < 0.05, **, P < 45 0.01, ***, P < 0.001, ****, P < 0.0001.
- 46
- 47 siC, siControl, siP γ , siPPAR γ , siU5, siUBR5. Error bars, mean \pm s.e.m. (B). siC, siControl. Two-way ANOVA test
- 48 with Fisher's LSD test (A-C). One-way ANOVA test with Fisher's LSD test (G). *, P < 0.05, **, P < 0.01, ***, P < 0.0
- **49** 0.001, ****, P < 0.0001.





Figure S3 PPARy promotes ATM signaling by increasing ATMIN ubiquitination in 293T cells. - Related to 53 Figure 2.

- 54 (A) Densitometry of HU-induced ATM signaling pathways, pATM, pKAP1, pSMC1, γH2AX levels with PPARγ or 55 UBR5 depletion.
- 56 (B) Representative immunoblots and densitometry data of DoxR-induced ATM signaling pathways, pATM, pKAP1,
- 57 pSMC1, yH2AX levels with PPARy or UBR5 depletions.
- 58 (C) Densitometry data of HU-induced ATMIN and pRPA2 with PPARy depletion.
- 59 (D) Densitometry data of HU-induced ATMIN and pRPA2 with UBR5 depletion.
- 60 (E) Representative immunoblots of endogenous IP of nuclear PPARy with Flag-ATMIN (aa1-354) with UBR5 61 depletion.
- 62 (F) Representative immunoblots of endogenous IP of nuclear PPARy or UBR5 with Flag-ATMIN (aa1-354) with
- 63 HU. The samples were harvested at the indicated time after HU treatment and lysates were separately incubated with 64 anti-PPARy or anti-UBR5.
- 65 (G) Representative immunoblots and densitometry data of restoration of K48-linked polyubiquitins with siRNA
- 66 (siPPARy#9)-resistant PPARy overexpression.





Fig. S4 PPARy depletion suppresses pATM and yH2AX foci formation with various DNA damage stimuli and 70 has no effects on cell cycle in primary endothelial cells. - Related to Figure 3.

<0.1% O

- Reoxy

- 71 (A) Densitometry data of HU-induced pATM with PPARy depletion in PAEC.
- 72 (B) Representative immunoblots and densitometry data of HU-induced pRPA2 (S4/8) and yH2AX protein levels
- 73 with PPAR γ depletion in PAEC.

- 74 (C) Densitometry data of restoration of pATM with siRNA-resistant PPARγ (siResPPARγ) overexpression in
- 75 HUVEC.
- 76 (D) Densitometry data of HU-induced pATM and pKAP1 with PPARγ or/and ATMIN depletion in PAEC.
- 77 (E) Confocal microscopy and triplicate quantitative data of effects of PPAR γ depletion on pATM foci formation 78 march HL (24 here) triplicate quantitative data of effects of PPAR γ depletion on pATM foci formation
- **78** upon HU (24 hours) treatment in PAEC.
- 79 (F) Confocal microscopy and triplicate quantitative data of effects of PPARγ depletion on γH2AX foci formation
- 80 upon HU (24 hours) treatment in PAEC.
- 81 (G) Confocal microscopy and triplicate quantitative data of effects of PPARγ depletion by multiple siRNAs on
- γH2AX foci formation upon HU (24 hours) treatment in PAEC. PPARγ siRNAs (#7-9) are three out of the four
 individual PPARγ siRNAs used in the siPγ pool.
- 84 (H) Flow cytometry analysis of EdU incorporation shows cell cycle profiles of cells with PPARγ depletion and with
- HU (24 hours) treatment in PAEC.
- 86 (I) Confocal microscopy and triplicate quantitative data of 8-oxo-dG foci upon hypoxia (24 hours) (< 0.1% O₂) and
- 87 10 min reoxygenation (Reoxy) in PAEC.
- 88 (J) Replicate quantitative data of pATM foci with hypoxia-reoxygenation as described in (I).
- 89 siC, siControl, siP γ , siPPAR γ . Error bars, mean \pm s.e.m. The line in the box-and-whisker plots marks the median and 90 whiskers correspond to the 10th to 90th percentiles (E-G, I-J). Two-way ANOVA with Fisher's LSD test (A-D).
- 91 Kruskal–Wallis ANOVA test with Dunn's test (E-G, I). Unpaired t test (J). *, P < 0.05, **, P < 0.01, ***, P < 0.001;
- **92** ****, P < 0.0001. Scale bars, E-G, 50µm; I, 20µm.





- Fig. S5 PPARy depletion leads to persistent pRPA2 and yH2AX foci after HU-induced damage which are 97 resolved by ATMIN depletion in PAEC. - Related to Figure 4.
- 98 (A) Replicate quantitative data of extended comet tail lengths in PPARy depleted cells after HU (6 hours) was 99 removed (recovery for 24 hours).
- (B) Replicate quantitative data of pRPA2 and YH2AX foci in PPARY depleted cells after HU (24 hours) was 100
- 101 removed. Cells were fixed at various recovery time points as indicated.
- (C) Replicate quantitative data of resolution of pRPA2 foci with ATMIN depletion in addition to PPARy depletion. 102
- 103 (D) Densitometry data show restoration of pRPA2 protein levels with ATMIN depletion in addition to PPARy
- 104 depletion.
- 105 siC, siControl, siP γ , siPPAR γ . Error bars, mean \pm s.e.m. The line in the box-and-whisker plots marks the median and
- whiskers correspond to the 10th to 90th percentiles (A-C). Kruskal–Wallis ANOVA test with Dunn's test (A-C). 106
- 107 Two-way ANOVA with Fisher's LSD test (D). *, P < 0.05, **, P < 0.01, ***, P < 0.001; ****, P < 0.0001, ns, not 108 significant.

109 Figure S6



110

111 Fig. S6 PPARy and ATMIN axis is impaired in PAEC from PAH patients. – Related to Figure 5.

(A) Phase-contrast microscopy shows healthy primary PAEC cultures established from explanted lungs of control

- 113 (unused donors) and PAH patient. Inserts indicate mitotic cells from the dotted square.
- (B) Replicate quantitative data of HU-induced pATM levels in control and PAH-PAEC.
- 115 (C) Densitometry data of ATMIN protein levels in control and PAH-PAEC.
- (D) Replicate quantitative data of pATM levels in control and PAH-PAEC with ATMIN depletion.
- 117 siC, siControl, siP γ , siPPAR γ . Error bars, mean \pm s.e.m. The line in the box-and-whisker plots marks the median and
- 118 whiskers correspond to the 10th to 90th percentiles (B,D). Kruskal–Wallis ANOVA test with Dunn's test (B,D).
- **119** Unpaired t test (C). *, P < 0.05, ***, P < 0.001; ****, P < 0.0001, ns, not significant.

| | | Adj. P | Gene | | |
|------------|--------|----------|---------|--|--|
| Uniprot ID | Log2FC | value | name | Protein name | |
| P37231 | 7.32 | 0 | PPARG | Peroxisome proliferator-activated receptor gamma | |
| P04637 | 6.9 | 0 | TP53 | Cellular tumor antigen p53 | |
| P11142 | 6.22 | 0 | HSPA8 | Heat shock cognate 71 kDa protein | |
| O95816 | 6.22 | 0 | BAG2 | BAG family molecular chaperone regulator 2 | |
| P19793 | 6.17 | 0 | RXRA | Retinoic acid receptor RXR-alpha | |
| P23396 | 5.86 | 0 | RPS3 | 40S ribosomal protein S3 | |
| P52272 | 5.18 | 0 | HNRNPM | Heterogeneous nuclear ribonucleoprotein M | |
| | | | | Heterogeneous nuclear ribonucleoprotein H, N-terminally | |
| P31943 | 5.08 | 0 | HNRNPH1 | processed | |
| P49411 | 4.97 | 0 | TUFM | Elongation factor Tu, mitochondrial | |
| P49368 | 4.82 | 0 | CCT3 | T-complex protein 1 subunit gamma | |
| Q92841 | 4.74 | 0 | DDX17 | Probable ATP-dependent RNA helicase DDX17 | |
| P08107 | 4.53 | 0 | HSPA1B | Heat shock 70 kDa protein 1A/1B | |
| P17987 | 4.38 | 0 | TCP1 | T-complex protein 1 subunit alpha | |
| P55072 | 3.98 | 0 | VCP | Transitional endoplasmic reticulum ATPase | |
| Q9UL15 | 3.91 | 0 | BAG5 | BAG family molecular chaperone regulator 5 | |
| Q08211 | 3.87 | 0 | DHX9 | ATP-dependent RNA helicase A | |
| P18669 | 3.74 | 0 | PGAM1 | Phosphoglycerate mutase 1 | |
| P48047 | 3.43 | 0 | ATP5O | ATP synthase subunit O, mitochondrial | |
| P52209 | 3.43 | 0 | PGD | 6-phosphogluconate dehydrogenase, decarboxylating | |
| Q9Y265 | 3.05 | 0 | RUVBL1 | RuvB-like 1 | |
| Q9Y230 | 3.03 | 0 | RUVBL2 | RuvB-like 2 | |
| P38646 | 3 | 0 | HSPA9 | Stress-70 protein, mitochondrial | |
| P11021 | 2.74 | 0 | HSPA5 | 78 kDa glucose-regulated protein | |
| P13796 | 2.65 | 0 | LCP1 | Plastin-2 | |
| P50990 | 2.65 | 0 | CCT8 | T-complex protein 1 subunit theta | |
| O14830 | 2.16 | 0 | PPEF2 | Serine/threonine-protein phosphatase with EF-hands 2 | |
| P47929 | 2.11 | 0 | LGALS7 | Galectin-7 | |
| P49959 | 2.08 | 0 | MRE11A | Meiotic recombination 11 MRE11A | |
| Q02880 | 2 | 0 | TOP2B | DNA topoisomerase 2-beta | |
| Q9H0A0 | 1.83 | 0 | NAT10 | N-acetyltransferase 10 | |
| Q9Y490 | 1.79 | 0 | TLN1 | Talin-1 | |
| P15927 | 1.58 | 0 | RPA2 | Replication protein A 32 kDa subunit | |
| P49916 | 1.55 | 0 | LIG3 | DNA ligase 3 | |
| Q9UBQ0 | 1.54 | 0 | VPS29 | Vacuolar protein sorting-associated protein 29 | |
| P62241 | 7.17 | 5.57E-15 | RPS8 | 40S ribosomal protein S8 | |
| Q86U86 | 5.1 | 1.02E-14 | PBRM1 | Protein polybromo-1 | |
| Q7Z2W4 | 5.06 | 1.02E-14 | ZC3HAV1 | Zinc finger CCCH-type antiviral protein 1 | |
| Q92945 | 4.55 | 1.02E-14 | KHSRP | Far upstream element-binding protein 2 | |
| | | | | PERQ amino acid-rich with GYF domain-containing | |
| Q6Y7W6 | 1.83 | 2.01E-14 | GIGYF2 | protein 2 | |
| P33993 | 4.09 | 2.95E-14 | MCM7 | DNA replication licensing factor MCM7 | |
| P17066 | 3.06 | 3.37E-14 | HSPA6 | Heat shock 70 kDa protein 6 | |
| Q13263 | 3.26 | 8.51E-14 | TRIM28 | Transcription intermediary factor 1-beta | |
| Q9H583 | 1.86 | 1.02E-13 | HEATR1 | HEAT repeat-containing protein 1, N-terminally processed | |
| P42704 | 1.71 | 1.05E-13 | LRPPRC | Leucine-rich PPR motif-containing protein, mitochondrial | |
| P62906 | 4.96 | 1.07E-13 | RPL10A | 60S ribosomal protein L10a | |
| Q14151 | 4.04 | 2.02E-13 | SAFB2 | Scaffold attachment factor B2 | |
| Q15393 | 3.32 | 3.40E-13 | SF3B3 | Splicing factor 3B subunit 3 | |
| P78316 | 2.24 | 3.40E-13 | NOP14 | Nucleolar protein 14 | |
| P62424 | 2.14 | 3.78E-13 | RPL7A | 60S ribosomal protein L7a | |

121 Table S1 High-confidence PPARy interactors identified from AP-MS. – Related to Figure 1; Figure S1.

| P32969 | 5.6 | 6.05E-13 | RPL9P7 | 60S ribosomal protein L9 |
|--------|------|----------|---------|--|
| P78347 | 4.3 | 6.89E-13 | GTF2I | General transcription factor II-I |
| Q99615 | 4.96 | 9.02E-13 | DNAJC7 | DnaJ homolog subfamily C member 7 |
| Q15029 | 3.75 | 9.05E-13 | EFTUD2 | 116 kDa U5 small nuclear ribonucleoprotein component |
| Q9NVP1 | 2.43 | 9.05E-13 | DDX18 | ATP-dependent RNA helicase DDX18 |
| 075368 | 1.91 | 1.10E-12 | SH3BGRL | SH3 domain-binding glutamic acid-rich-like protein |
| O95786 | 2.4 | 1.11E-12 | DDX58 | Probable ATP-dependent RNA helicase DDX58 |
| P28702 | 4.1 | 1.50E-12 | RXRB | Retinoic acid receptor RXR-beta |
| P61978 | 2.25 | 1.66E-12 | HNRNPK | Heterogeneous nuclear ribonucleoprotein K |
| Q96EY1 | 5.01 | 2.90E-12 | DNAJA3 | DnaJ homolog subfamily A member 3, mitochondrial |
| Q8N1F7 | 2.57 | 3.12E-12 | NUP93 | Nuclear pore complex protein Nup93 |
| O60934 | 2.32 | 8.83E-12 | NBS1 | Nibrin |
| O00231 | 4.86 | 1.18E-11 | PSMD11 | 26S proteasome non-ATPase regulatory subunit 11 |
| Q12906 | 5.8 | 1.22E-11 | ILF3 | Interleukin enhancer-binding factor 3 |
| Q92878 | 1.77 | 1.47E-11 | RAD50 | DNA repair protein RAD50 |
| | | | | SWI/SNF-related matrix-associated actin-dependent |
| O60264 | 1.76 | 2.00E-11 | SMARCA5 | regulator of chromatin subfamily A member 5 |
| O15042 | 5.15 | 2.02E-11 | U2SURP | U2 snRNP-associated SURP motif-containing protein |
| O76021 | 2.28 | 2.53E-11 | RSL1D1 | Ribosomal L1 domain-containing protein 1 |
| P62191 | 3.77 | 3.35E-11 | PSMC1 | 26S protease regulatory subunit 4 |
| | | | | Probable 28S rRNA (cytosine(4447)-C(5))- |
| P46087 | 3.91 | 3.67E-11 | NOP2 | methyltransferase |
| Q9Y2R4 | 3.68 | 4.88E-11 | DDX52 | Probable ATP-dependent RNA helicase DDX52 |
| Q9BVJ6 | 4.41 | 4.97E-11 | UTP14A | U3 small nucleolar RNA-associated protein 14 homolog A |
| 015144 | 2.26 | 5.08E-11 | ARPC2 | Actin-related protein 2/3 complex subunit 2 |
| Q12905 | 3.1 | 5.40E-11 | ILF2 | Interleukin enhancer-binding factor 2 |
| P62701 | 4.93 | 5.77E-11 | RPS4X | 40S ribosomal protein S4, X isoform |
| Q9BZE4 | 2.7 | 7.08E-11 | GTPBP4 | Nucleolar GTP-binding protein 1 |
| 075367 | 2.76 | 9.21E-11 | H2AFY | Core histone macro-H2A.1 |
| P15924 | 1.62 | 9.21E-11 | DSP | Desmoplakin |
| Q9Y2X3 | 4.4 | 9.27E-11 | NOP58 | Nucleolar protein 58 |
| Q8WVV4 | 1.54 | 1.01E-10 | POF1B | Protein POF1B |
| P17931 | 2.23 | 2.46E-10 | LGALS3 | Galectin-3 |
| Q9BVP2 | 2.07 | 3.14E-10 | GNL3 | Guanine nucleotide-binding protein-like 3 |
| P26038 | 2.36 | 3.16E-10 | MSN | Moesin |
| P06702 | 1.91 | 3.16E-10 | S100A9 | Protein S100-A9 |
| | | | HSP90AA | |
| P07900 | 3.08 | 3.80E-10 | 1 | Heat shock protein HSP 90-alpha |
| P31689 | 3.87 | 4.49E-10 | DNAJA1 | DnaJ homolog subfamily A member 1 |
| 015511 | 2.34 | 5.01E-10 | ARPC5 | Actin-related protein 2/3 complex subunit 5 |
| O15160 | 3.33 | 5.70E-10 | POLR1C | DNA-directed RNA polymerases I and III subunit RPAC1 |
| O43818 | 1.72 | 9.22E-10 | RRP9 | U3 small nucleolar RNA-interacting protein 2 |

Proteins co-purified with Flag-PPARγ from 293T nuclear extracts were detected by mass spectrometry and analyzed
 as described in Experimental Procedures. Proteins in red were validated in Fig. 1c. Log₂FC (Fold-Change) indicates

125 the fold enrichment of proteins immunoprecipitated from Flag-PPAR γ expressing cells as compared to Flag-vector

expressing cells. The adjusted (adj.) P values are indicated and the data was obtained from four independent

127 experiments. Proteins are listed by their adj. P values.

128 Table S2

| 129 | Biological functions associated with the high-confidence PPARy interactome. – Related to Figure 1; Figure |
|-----|---|
| 130 | S1 |

Uniprot ID Gene name **Biological function name** 015144 ARPC2 Actin cytoskeleton organization 015511 ARPC5 Actin cytoskeleton organization P47929 LGALS7 Cell-cell interaction Q8WVV4 POF1B Cell-cell interaction Q9Y490 TLN1 Cell-cell interaction P48047 ATP50 Cellular metabolism 095816 BAG2 Cellular metabolism Q9UL15 BAG5 Cellular metabolism P18669 PGAM1 Cellular metabolism P52209 PGD Cellular metabolism P37231 PPARG Cellular metabolism P19793 RXRA Cellular metabolism P28702 RXRB Cellular metabolism Cellular metabolism P49411 TUFM Q9UBQ0 VPS29 Cellular metabolism Q08211 DHX9 DNA damage response and replication P31689 DNAJA1 DNA damage response and replication DNA damage response and replication Q96EY1 DNAJA3 075367 H2AFY DNA damage response and replication P07900 HSP90AA1 DNA damage response and replication P08107 HSPA1B DNA damage response and replication P11142 HSPA8 DNA damage response and replication Q92945 KHSRP DNA damage response and replication P49916 LIG3 DNA damage response and replication P42704 LRPPRC DNA damage response and replication P33993 MCM7 DNA damage response and replication P49959 MRE11A DNA damage response and replication 060934 NBN DNA damage response and replication Q8N1F7 NUP93 DNA damage response and replication Q86U86 PBRM1 DNA damage response and replication P62191 PSMC1 DNA damage response and replication O00231 PSMD11 DNA damage response and replication Q92878 RAD50 DNA damage response and replication P15927 RPA2 DNA damage response and replication Q9Y265 RUVBL1 DNA damage response and replication Q9Y230 RUVBL2 DNA damage response and replication Q14151 SAFB2 DNA damage response and replication 060264 SMARCA5 DNA damage response and replication TOP2B Q02880 DNA damage response and replication P04637 TP53 DNA damage response and replication TRIM28 Q13263 DNA damage response and replication VCP P55072 DNA damage response and replication Innate immune response O95786 DDX58 P13796 LCP1 Innate immune response P17931 LGALS3 Innate immune response P06702 S100A9 Innate immune response Q7Z2W4 ZC3HAV1 Innate immune response Q92841 DDX17 mRNA metabolic process and RNA processing Q9NVP1 DDX18 mRNA metabolic process and RNA processing Q9Y2R4 DDX52 mRNA metabolic process and RNA processing

| Q15029 | EFTUD2 | mRNA metabolic process and RNA processing |
|--------|---------|---|
| Q6Y7W6 | GIGYF2 | mRNA metabolic process and RNA processing |
| Q9BVP2 | GNL3 | mRNA metabolic process and RNA processing |
| Q9BZE4 | GTPBP4 | mRNA metabolic process and RNA processing |
| Q9H583 | HEATR1 | mRNA metabolic process and RNA processing |
| P31943 | HNRNPH1 | mRNA metabolic process and RNA processing |
| P61978 | HNRNPK | mRNA metabolic process and RNA processing |
| P52272 | HNRNPM | mRNA metabolic process and RNA processing |
| Q12905 | ILF2 | mRNA metabolic process and RNA processing |
| Q12906 | ILF3 | mRNA metabolic process and RNA processing |
| Q9H0A0 | NAT10 | mRNA metabolic process and RNA processing |
| P78316 | NOP14 | mRNA metabolic process and RNA processing |
| P46087 | NOP2 | mRNA metabolic process and RNA processing |
| Q9Y2X3 | NOP58 | mRNA metabolic process and RNA processing |
| P62906 | RPL10A | mRNA metabolic process and RNA processing |
| P62424 | RPL7A | mRNA metabolic process and RNA processing |
| P32969 | RPL9P7 | mRNA metabolic process and RNA processing |
| P23396 | RPS3 | mRNA metabolic process and RNA processing |
| P62701 | RPS4X | mRNA metabolic process and RNA processing |
| P62241 | RPS8 | mRNA metabolic process and RNA processing |
| O43818 | RRP9 | mRNA metabolic process and RNA processing |
| O76021 | RSL1D1 | mRNA metabolic process and RNA processing |
| Q15393 | SF3B3 | mRNA metabolic process and RNA processing |
| O15042 | U2SURP | mRNA metabolic process and RNA processing |
| Q9BVJ6 | UTP14A | mRNA metabolic process and RNA processing |
| P49368 | CCT3 | Protein folding |
| P50990 | CCT8 | Protein folding |
| Q99615 | DNAJC7 | Protein folding |
| P15924 | DSP | Protein folding |
| P11021 | HSPA5 | Protein folding |
| P17066 | HSPA6 | Protein folding |
| P38646 | HSPA9 | Protein folding |
| P26038 | MSN | Protein folding |
| P17987 | TCP1 | Protein folding |
| P78347 | GTF2I | NA |
| O15160 | POLR1C | NA |
| O14830 | PPEF2 | NA |
| O75368 | SH3BGRL | NA |

Biological functions enriched among the top ranked 87 PPARγ interactors defined in Supplementary Table 1. NA, not available.

135 Table S3

136 Tandem affinity purification identified proteins interacting with PPARγ and NBS1 in unperturbed cells. –

137 Related to Figure 1.

| Uniprot ID | Log2FC | Adj. P value | Gene name | Protein name |
|------------|--------|--------------|-----------|--|
| O60934 | 6.24 | 0 | NBS1 | Nibrin |
| P37231 | 6.03 | 0 | PPARG | Peroxisome proliferator-activated receptor gamma |
| P49959 | 5.22 | 0 | MRE11A | Meiotic recombination 11 MRE11A |
| Q92878 | 5.01 | 0 | RAD50 | DNA repair protein RAD50 |
| O95816 | 3.7 | 1.71E-08 | BAG2 | BAG family molecular chaperone regulator 2 |
| Q9UL15 | 2.9 | 4.03E-07 | BAG5 | BAG family molecular chaperone regulator 5 |
| 075594 | 2.56 | 2.25E-02 | PGLYRP1 | Peptidoglycan recognition protein 1 |
| P04637 | 2.46 | 7.99E-09 | TP53 | Cellular tumor antigen p53 |
| P62269 | 2.2 | 0 | RPS18 | 40S ribosomal protein S18 |
| | | | | Complement component 1 Q subcomponent-binding |
| Q07021 | 2.1 | 2.05E-08 | C1QBP | protein, mitochondrial |
| P23588 | 1.96 | 4.10E-10 | EIF4B | Eukaryotic translation initiation factor 4B |
| Q02878 | 1.93 | 0 | RPL6 | 60S ribosomal protein L6 |
| P18124 | 1.9 | 1.60E-13 | RPL7 | 60S ribosomal protein L7 |
| P34932 | 1.84 | 0 | HSPA4 | Heat shock 70 kDa protein 4 |
| P50914 | 1.8 | 0 | RPL14 | 60S ribosomal protein L14 |
| O95071 | 1.8 | 3.37E-02 | UBR5* | E3 ubiquitin-protein ligase UBR5 |
| P98175 | 1.78 | 4.19E-11 | RBM10 | RNA-binding protein 10 |
| P62701 | 1.66 | 7.94E-07 | RPS4X | 40S ribosomal protein S4, X isoform |
| P62333 | 1.65 | 2.25E-03 | PSMC6* | 26S protease regulatory subunit 10B |
| Q9Y2W1 | 1.55 | 7.34E-11 | THRAP3* | Thyroid hormone receptor-associated protein 3 |
| P11142 | 1.54 | 0 | HSPA8 | Heat shock cognate 71 kDa protein |

138

139 Proteins were co-purified with PPARγ-2xStrep and sequentially with Flag-NBS1 from 293T whole cell extracts

140 [unperturbed cells or with HU treatment (Supplementary Table 4)]. Log₂FC indicates the fold enrichment of proteins

immunoprecipitated from the PPARγ-2xStrep and Flag-NBS1 expressing cells as compared to GFP-Strep-Flag

expressing cells (negative control). The adjusted P value is indicated and the data were obtained from three independent experiments

143 independent experiments.

144 * indicates proteins specifically enriched in unperturbed cells but not present in the HU treated cells. THRAP3 and

145 UBR5 (red) are validated in Fig. 1e, f. Proteins are listed by the Log₂FC.

146 Table S4

147 Tandem affinity purification identified proteins interacting with PPARγ and NBS1 upon HU treatment. –

148 Related to Figure 1.

| | 5 | | | |
|-------------------|--------|--------------|-----------|--|
| Uniprot ID | Log2FC | Adj. P value | Gene name | Protein name |
| O60934 | 6.25 | 0 | NBS1 | Nibrin |
| P37231 | 6.09 | 0 | PPARG | Peroxisome proliferator-activated receptor gamma |
| P49959 | 5.02 | 0 | MRE11A | Meiotic recombination 11 MRE11A |
| Q92878 | 4.78 | 0 | RAD50 | DNA repair protein RAD50 |
| O95816 | 3.88 | 6.05E-09 | BAG2 | BAG family molecular chaperone regulator 2 |
| Q9UL15 | 3.65 | 7.27E-08 | BAG5 | BAG family molecular chaperone regulator 5 |
| Q92552 | 3.16 | 3.37E-02 | MRPS27* | 28S ribosomal protein S27, mitochondrial |
| 075594 | 2.7 | 2.17E-02 | PGLYRP1 | Peptidoglycan recognition protein 1 |
| Q02878 | 2.61 | 0 | RPL6 | 60S ribosomal protein L6 |
| P18124 | 2.58 | 0 | RPL7 | 60S ribosomal protein L7 |
| | | | | Complement component 1 Q subcomponent-binding |
| Q07021 | 2.36 | 1.18E-09 | C1QBP | protein, mitochondrial |
| P04637 | 2.08 | 6.15E-07 | TP53 | Cellular tumor antigen p53 |
| P50914 | 2.07 | 0 | RPL14 | 60S ribosomal protein L14 |
| P43686 | 1.89 | 1.08E-07 | PSMC4* | 26S protease regulatory subunit 6B |
| Q9BRT6 | 1.87 | 4.32E-02 | LLPH* | Protein LLP homolog |
| O60318 | 1.83 | 2.30E-02 | MCM3AP* | Germinal-center associated nuclear protein |
| P11388 | 1.82 | 3.49E-09 | TOP2A* | DNA topoisomerase 2-alpha |
| P23588 | 1.79 | 1.21E-09 | EIF4B | Eukaryotic translation initiation factor 4B |
| P62269 | 1.78 | 0 | RPS18 | 40S ribosomal protein S18 |
| P98175 | 1.76 | 1.56E-11 | RBM10 | RNA-binding protein 10 |
| Q75N03 | 1.73 | 1.62E-02 | CBLL1* | E3 ubiquitin-protein ligase Hakai |
| P40429 | 1.71 | 2.38E-02 | RPL13A* | 60S ribosomal protein L13a |
| Q02880 | 1.7 | 3.50E-04 | TOP2B* | DNA topoisomerase 2-beta |
| P36578 | 1.69 | 9.59E-14 | RPL4* | 60S ribosomal protein L4 |
| | | | | Nicotinamide/nicotinic acid mononucleotide |
| Q9HAN9 | 1.67 | 3.64E-04 | NMNAT1* | adenylyltransferase 1 |
| P62917 | 1.65 | 0 | RPL8* | 60S ribosomal protein L8 |
| Q07020 | 1.64 | 6.87E-10 | RPL18* | 60S ribosomal protein L18 |
| P62266 | 1.62 | 6.37E-07 | RPS23* | 40S ribosomal protein S23 |
| P62847 | 1.61 | 3.98E-09 | RPS24* | 40S ribosomal protein S24 |
| P34932 | 1.61 | 8.63E-14 | HSPA4 | Heat shock 70 kDa protein 4 |
| P62701 | 1.59 | 9.46E-07 | RPS4X | 40S ribosomal protein S4, X isoform |
| P11142 | 1.58 | 0 | HSPA8 | Heat shock cognate 71 kDa protein |
| P62158 | 1.56 | 2.83E-06 | CALM2* | Calmodulin |
| P62249 | 1.55 | 5.53E-09 | RPS16* | 40S ribosomal protein S16 |
| P62241 | 1.54 | 1.43E-08 | RPS8* | 40S ribosomal protein S8 |
| P49368 | 1.51 | 2.20E-02 | CCT3* | T-complex protein 1 subunit gamma |

149

150 Proteins were co-purified with PPARγ-2xStrep and sequentially with Flag-NBS1 from 293T whole cell extracts with

151 HU treatment. Log₂FC (Fold-Change) indicates the fold enrichment of proteins immunoprecipitated from the

152 PPARγ-2xStrep and Flag-NBS1 expressing cells as compared to GFP-Strep-Flag expressing cells (negative control).

153 The adjusted P value is indicated and the data were obtained from three independent experiments. * indicates

154 proteins specifically enriched in the HU treated cells but not present in unperturbed cells. Proteins are listed by the 155 Log₂FC.

156 157 158 Table S5 – Related to STAR Methods.

Characteristics of (a) control subjects and (b) PAH patients used in this study.

(a) Control

| | Cells/ | | Age (yr)/ | Race/ | |
|------------|---------|------------|-----------|-----------|--------------------------------------|
| Control ID | Tissues | Assays | Gender | Ethnicity | Cause of Death |
| | | | | White/ | Grade 4 subarachnoid hemorrhage, |
| | | | | Non- | ruptured anterior cerebral artery |
| Control-1 | Tissue | IF | 41/F | Hispanic | aneurysm |
| | | | | White/ | |
| | | | | Non- | |
| Control-2 | Tissue | IF | 43/M | Hispanic | Fatal gunshot to head |
| | | | | White/ | |
| | | | | Non- | |
| Control-3 | Tissue | IF | 57/F | Hispanic | Intracranial hemorrhage/stroke |
| | | | | White/ | |
| | | | | Non- | |
| Control-4 | Tissue | IF | 28/F | Hispanic | MVC-anoxia |
| | | | | White/ | |
| | | | | Non- | |
| Control-5 | SPAEC | Comet | 47/M | Hispanic | Head trauma-bicycle vs. car accident |
| | | | | White/ | |
| | | | | Non- | |
| Control-6 | Tissue | IF | 56/F | Hispanic | Cerebrovascular accident |
| | | | | Unknown/ | |
| | | | | Hispanic | |
| Control-7 | SPAEC | Comet | 55/F | or Latino | Cerebrovascular stroke |
| | | IF, comet, | | White/ | |
| | Tissue/ | protein | | Non- | |
| Control-8 | LPAEC | expression | 57-F | Hispanic | Acute myocardial infarction |
| | | | | Unknown/ | |
| | | | | Non- | |
| Control-9 | LPAEC | Comet | 12/M | Hispanic | Head trauma rollover MVC ejection |
| | | | | White/ | |
| | | | | Non- | |
| Control-10 | LPAEC | Comet | 49/M | Hispanic | Head trauma |
| | | | | White/ | |
| | | Protein | | Non- | |
| Control-11 | SPAEC | expression | 33/F | Hispanic | Head trauma. Blunt injury. |

| | | | | Unknown/ | |
|-------------|-------|-------------|------|-----------|----------------------------|
| | | IP, protein | | Hispanic | |
| Control-12 | LPAEC | expression | 54/M | or Latino | Cerebrovascular/stroke ICH |
| | | | | Asian/ | |
| | | IP, protein | | Non- | |
| Control-13 | LPAEC | expression | 34/F | Hispanic | Cerebrovascular/stroke ICH |
| | | | | White/ | |
| | | | | Non- | |
| Control-14 | LPAEC | IP | 1/M | Hispanic | Anoxia/drowning |
| | | | | White/ | |
| | | IP, protein | | Non- | |
| Control-15* | LPAEC | expression | 35/M | Hispanic | Gunshot wound |
| | | IP, protein | | Asian/Un | |
| Control-16 | LPAEC | expression | 46/M | known | Cerebrovascular/stroke ICH |

(b) PAH patients

| | | | | | | | | | 6 Min Walkc | |
|------------|--------------------|----------------------------|---------------------|--|-----------|-------------------|--------------|----------------|-----------------|---|
| Patient ID | Cells/ Tissues | Assays | Age (yr)/ Gender | Race/ Ethnicity | Diagnosis | BMPR2 mutation | (s/d/m)PAPa | PVRb (mmHg) | (Wood Units) | PAH Medications (m), up to transplant date |
| | | | | White/ Non- | | | | | | |
| PAH-1 | Tissue | IF | 15-F | Hispanic | IPAH | No | (175/66/102) | 25.24 | 387 | sildenafil, epoprostenol |
| PAH-2 | Tissue | IF | 40-F | White/ Non- Hispanic | IPAH | No | (84/26/47) | NA | 294 | ambrisentan, sildenafil, iloprost, epoprostenol |
| РАН-3 | LPAEC | Protein expressoo pm | 33-F | Black or African American/ Non- Hispanic | FPAH | Yes | (75/33/48) | 15.57 | 326.1 | epoprostenol, bosentan, sildenafil, treprostinil |
| PAH-4 | Tissue | IF | 56-F | White/ Non- Hispanic | IPAH | No | (83/39/57) | 11.41 | 137.2 | sildenafil, ambrisentan, treprostinil |
| PAH-5 | Tissue,S/ LPAEC | IF, comet, | 27-F | White/ Non- Hispanic | IPAH | Yes | (110/49/69) | 12.11 | 359.7 | sildenafil, treprostinil, bosentan, iloprost |

| | CDAEC | | 40.14 | White/ Hispanic | IDAU | N | (110/40/64) | 72 | 120 | sildenafil, ambrisentan, |
|---------|---------|-------------|---------------|--------------------|-----------|------|-------------|-------|-------|--------------------------|
| PAH-6 | SPAEC | Comet | 40-M | or Latino | IPAH | NO | (118/49/64) | /3 | 420 | sildenafil, sitaxsentan, |
| | | | | W 71.:4 - / | | | | | | ambrisentan, |
| | | | | Non- | | | | | | (investigational), |
| PAH-7 | SPAEC | Comet | 37-M | Hispanic | FPAH | Yes | (119/51/77) | 14.22 | 309 | treprostinil |
| | | Comet, IP, | | White/ | | | | | | |
| PAH-8 | LPAEC | expression | 32-F | Non- Hispanic | IPAH | No | (68/38/49) | 15.34 | 238 | bosentan, epoprostenol |
| | | | | | | | | | | |
| | | IF comet | | White/ | АРАН- | | | | | |
| | Tissue/ | IP, protein | | Non- | Congenita | | | | | |
| PAH-9 | LPAEC | expression | 30-M | Hispanic | 1 ASD | No | (128/60/85) | NA | 160 | sildenafil, bosentan |
| | | | | White/ | | | | | | |
| DALL 10 | IDAEC | IP, protein | 16 F | Non- | IDAII | | | | 102.4 | sildenafil, subcutaneous |
| PAH-10 | LPAEC | expression | 10-F | Hispanic | IPAH | IN/A | (NA/NA/95) | IN/A | 102.4 | treprostinii |
| | | | | White/ | | | | | | sildenafil, ambrisentan, |
| | | Protein | | Hispanic | APAH- | | | | | bosentan, treprostinil, |
| PAH-11 | LPAEC | expression | 50-F | or Latino | D&T | N/A | (113/43/65) | 16.18 | 384 | epoprostenol |
| | | | | White/ | | | | | | |
| | TRADE | Protein | | Non- | | | | 10.65 | | sildenafil, ambrisentan, |
| PAH-12 | LPAEC | expression | 22 - F | Hispanic | FPAH | Yes | (98/46/66) | 10.19 | 506 | tadalafil, treprostinil |

162 a (s/d/m) PAP= Systolic, diastolic, and mean pulmonary arterial pressure. b PVR= Pulmonary vascular resistance. c 6 min walk = distance walked in six minutes.

a-c Values are closest to transplant date. * Control line that did not meet PHBI inclusion criteria due to known history of amphetamine/methamphetamine use.

164 Abbreviations: SPAEC, small pulmonary arterial endothelial cells (<1 mm by dissection); LPAEC, large PAEC (>1 mm); IF, immunofluorescence; IP,

165 immunoprecipitation; F, female; M, male; MVC, motor vehicle accident; ICH, intracranial hemorrhage; IPAH, idiopathic pulmonary arterial hypertension;

166 FPAH, familiar PAH; APAH, associated PAH; ASD, atrial septal defect ; D&T, drug and toxin; NA, not available.

168 169 Table S6 – Related to STAR Methods.Table of Oligonucleotides used.

| Oligo | Sequence (5'-3') | Description |
|-------------------------------------|----------------------------|---|
| PPARγ- | GTGGCCATCCGCATCTGACAGGGCTG | Primer used for generating Flag-PPARvALBD |
| delLBD F | CCAGTTTCG | |
| PPARγ- | CGAAACTGGCAGCCCTGTCAGATGC | Primer used for generating Flag-PPARγΔLBD |
| delLBD_R | GGATGGCCAC | |
| 2Strep- | TAGTCCAGTGTGGTGGAATTCGCCGC | Primer used for generating 2xStrep-PPARy |
| PPARγ-F | CATGACCATGGTTGACACAG | |
| 2Strep- | CACCGCCTCCCTCGAGCGGCCGCACG | Primer used for generating 2xStrep-PPARy |
| PPARγ-R | | |
| SIRES- | ATGACAGCGATCICGCAATATITATT | Primer used for generating siRNA-resistant-Flag- |
| $PPAR\gamma_F$ | | $\frac{PPAR\gamma}{P}$ |
| SIKES- | | Primer used for generating siRNA-resistant-Flag- |
| $PPAR\gamma_R$ | | PPARγ Primer used for quantitative real time PCP |
| $\Gamma \Gamma A R \gamma_{\Gamma}$ | TACCCACACATCCACCCACCTCA | Primer used for quantitative real-time PCR |
| ΡΡΑΚγ_Κ | | Primer used for quantitative real-time PCR |
| UBR5_F | | Primer used for quantitative real-time PCR |
| UBR5_R | AITCGAGGIGGCCIGIAIIG | Primer used for quantitative real-time PCR |
| ATMIN_F | AACAGCACTGCAGTCTCACA | Primer used for quantitative real-time PCR |
| ATMIN_R | CTGGTCTAGGGATTGGTTGGT | Primer used for quantitative real-time PCR |
| NBS1_F | CACTCACCTTGTCATGGTATCAG | Primer used for quantitative real-time PCR |
| NBS1_R | CTGCTTCTTGGACTCAA CTGC | Primer used for quantitative real-time PCR |
| PLIN2_F | ATGGCATCCGTTGCAGTTGAT | Primer used for quantitative real-time PCR |
| PLIN2_R | GGACATGAGGTCATACGTGGAG | Primer used for quantitative real-time PCR |
| ACOX1_F | GGAACTCACCTTCGAGGCTTG | Primer used for quantitative real-time PCR |
| ACOX1_R | TTCCCCTTAGTGATGAGCTGG | Primer used for quantitative real-time PCR |
| CPT1B_F | CCTGCTACATGGCAACTGCTA | Primer used for quantitative real-time PCR |
| CPT1B_R | AGAGGTGCCCAATGATGGGA | Primer used for quantitative real-time PCR |
| ACSF2_F | ATGGCTGTCTACGTCGGG | Primer used for quantitative real-time PCR |
| ACSF2_R | GACCATGCGATCCACCTCTC | Primer used for quantitative real-time PCR |
| ME1 F | CTGCTGACACGGAACCCTC | Primer used for quantitative real-time PCR |
| ME1 R | GATCTCCTGACTGTTGAAGGAAG | Primer used for quantitative real-time PCR |
| CFD F | GACACCATCGACCACGACC | Primer used for quantitative real-time PCR |
| CFD R | GCCACGTCGCAGAGAGTTC | Primer used for quantitative real-time PCR |
| IDH3A F | GGACCTGGAGGAAAGTGGAT | Primer used for quantitative real-time PCR |
| IDH3A R | GCTGCTATTGGGGTCTTCAA | Primer used for quantitative real-time PCR |
| ß-actin F | CATGCCATCCTGCGTCTGGA | Primer used for quantitative real-time PCR |
| β-actin R | CCGTGGCCATCTCTTGCTCG | Primer used for quantitative real-time PCR |